From: Impact of different anti-HCV regimens on platelet count during treatment in Egyptian patients
 | Group |  | ||
---|---|---|---|---|
SIM/SOF | SOF/RBV | Triple | p value | |
Age (years) | 55.05 ± 8.00 | 53.93 ± 9.27 | 53.55 ± 7.56 | 0.764 |
Weight (Kg) | 81.73 ± 15.29 | 81.35 ± 12.41 | 80.05 ± 13.55 | 0.626 |
Height (m) | 1.64 ± .08 | 1.66 ± .10 | 1.68 ± .09 | 0.092 |
BMI (Kg/m2) | 30.36 ± 6.09 | 29.81 ± 4.39 | 28.40 ± 4.48 | 0.099 |
HCV positivity (years) | 2.26 ± 2.81 | 6.67 ± 6.30 * | 4.18 ± 5.85 | < 0.001 |
Fib 4 calculation | 5.10 ± 2.78 | 7.77 ± 3.79 * | 3.74 ± 1.43 *# | < 0.001 |
Baseline platelets (*1000/mm3) | 111.84 ± 40.35 | 77.18 ± 18.01 * | 136.89 ± 31.70 *# | < 0.001 |
Baseline TLC (*1000/mm3) | 4.89 ± 1.35 | 4.89 ± 1.52 | 5.97 ± 1.99 *# | 0.002 |
Baseline ANC (*1000/mm3) | 2.64 ± .95 | 2.59 ± 1.01 | 3.11 ± 1.27 *# | 0.028 |
Baseline Hb (g/dl) | 12.63 ± 1.38 | 12.97 ± 1.69 | 13.86 ± 1.58 *# | < 0.001 |
Baseline Alt (IU/l) | 57.35 ± 39.05 | 64.52 ± 37.95 | 75.04 ± 58.82 | 0.198 |
Baseline Ast (IU/l) | 65.58 ± 36.44 | 78.14 ± 42.81 | 72.91 ± 51.74 | 0.106 |
Baseline Bil T (mg/dl) | .99 ± .39 | 1.18 ± .57 | .99 ± .69 # | 0.024 |
Baseline Alb (g/dl) | 3.50 ± .46 | 3.44 ± .46 | 3.95 ± .44 *# | < 0.001 |
Baseline PC (%) | 79.38 ± 12.46 | 75.20 ± 13.93 | 81.98 ± 15.38 # | 0.015 |
Baseline Creat (mg/dl) | .74 ± .20 | .80 ± .19 | .83 ± .23 | 0.088 |
Creat clearance (ml/min) | 120.94 ± 33.11 | 116.76 ± 31.33 | 113.68 ± 30.77 | 0.663 |
Baseline HCV RNA by PCR (IU/ml) | 949,173.30 ± 1195,220.29 | 1,051,988.49 ± 1,824,411.25 | 2,473,014.05 ± 6631,407.20 | 0.256 |
TSH (μIU/ml) | 1.92 ± 1.46 | 1.97 ± 2.05 | 1.67 ± 1.20 | 0.518 |
Alpha fetoprotien (IU/l) | 15.66 ± 22.75 | 28.92 ± 29.11 * | 21.00 ± 30.15 | 0.001 |